Skip to main content
    • Aa
    • Aa
  • Access
  • Cited by 75
  • Cited by
    This article has been cited by the following publications. This list is generated based on data provided by CrossRef.

    Migdal, Alexandra L. and Abrahamson, Martin J. 2016. Principles of Diabetes Mellitus.

    Signoret, Cathy and Jacobs, Heidi 2014. Polysaccharides.

    Torekov, S. S. Holst, J. J. and Ehlers, M. R. 2014. Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, Vol. 16, Issue. 5, p. 451.

    Umapathysivam, M. M. Lee, M. Y. Jones, K. L. Annink, C. E. Cousins, C. E. Trahair, L. G. Rayner, C. K. Chapman, M. J. Nauck, M. A. Horowitz, M. and Deane, A. M. 2014. Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia. Diabetes, Vol. 63, Issue. 2, p. 785.

    Walter, C. P. Bleske, B. E. and Dorsch, M. P. 2014. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. Journal of Clinical Pharmacy and Therapeutics, Vol. 39, Issue. 5, p. 475.

    Werner, Ulrich 2014. Effects of the GLP-1 receptor agonist lixisenatide on postprandial glucose and gastric emptying – preclinical evidence. Journal of Diabetes and its Complications, Vol. 28, Issue. 1, p. 110.

    Zhang, Yi Liu, Ju Yao, Jianliang Ji, Gang Qian, Long Wang, Jing Zhang, Guansheng Tian, Jie Nie, Yongzhan Zhang, Yi Gold, Mark and Liu, Yijun 2014. Obesity: Pathophysiology and Intervention. Nutrients, Vol. 6, Issue. 11, p. 5153.

    Colon-Gonzalez, Francheska Kim, Gilbert W. Lin, Jieru E. Valentino, Michael A. and Waldman, Scott A. 2013. Obesity pharmacotherapy: What is next?. Molecular Aspects of Medicine, Vol. 34, Issue. 1, p. 71.

    González Jiménez, Emilio 2013. Obesidad: análisis etiopatogénico y fisiopatológico. Endocrinología y Nutrición, Vol. 60, Issue. 1, p. 17.

    González Jiménez, Emilio 2013. Obesity: Etiologic and pathophysiological analysis. Endocrinología y Nutrición (English Edition), Vol. 60, Issue. 1, p. 17.

    Kim, Gilbert W Lin, Jieru E Blomain, Erik S and Waldman, Scott A 2013. New advances in models and strategies for developing anti-obesity drugs. Expert Opinion on Drug Discovery, Vol. 8, Issue. 6, p. 655.

    Näslund, E. and Hellström, P.M. 2013. Satiation, Satiety and the Control of Food Intake.

    Nicolini, Andrea Ferrari, Paola Masoni, Maria Chiara Fini, Milena Pagani, Stefania Giampietro, Ottavio and Carpi, Angelo 2013. Malnutrition, anorexia and cachexia in cancer patients: A mini-review on pathogenesis and treatment. Biomedicine & Pharmacotherapy, Vol. 67, Issue. 8, p. 807.

    Ueda, Shin-ya Nakahara, Hidehiro and Miyamoto, Tadayoshi 2013. Effects of exercise on glucagon-like peptide-1 (GLP-1). The Journal of Physical Fitness and Sports Medicine, Vol. 2, Issue. 2, p. 221.

    Bourey, Raymond and Lambert, Charles 2012. Obesity.

    Fineman, M.S. Cirincione, B.B. Maggs, D. and Diamant, M. 2012. GLP-1 based therapies: differential effects on fasting and postprandial glucose. Diabetes, Obesity and Metabolism, Vol. 14, Issue. 8, p. 675.

    Silva, Akila De and Bloom, Stephen R. 2012. Gut Hormones and Appetite Control: A Focus on PYY and GLP-1 as Therapeutic Targets in Obesity. Gut and Liver, Vol. 6, Issue. 1, p. 10.

    Svendsen, Pernille F. Jensen, Frank K. Holst, Jens J. Haugaard, Steen B. Nilas, Lisbeth and Madsbad, Sten 2012. The effect of a very low calorie diet on insulin sensitivity, beta cell function, insulin clearance, incretin hormone secretion, androgen levels and body composition in obese young women. Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 72, Issue. 5, p. 410.

    Hellström, P. M. 2011. GLP-1 playing the role of a gut regulatory compound. Acta Physiologica, Vol. 201, Issue. 1, p. 151.

    Horner, K. M. Byrne, N. M. Cleghorn, G. J. Näslund, E. and King, N. A. 2011. The effects of weight loss strategies on gastric emptying and appetite control. Obesity Reviews, Vol. 12, Issue. 11, p. 935.


Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects

  • Erik Näslund (a1), N. King (a2), S. Mansten (a3), N. Adner (a3), J. J. Holst (a4), M. Gutniak (a3) and P. M. Hellström (a5)
  • DOI:
  • Published online: 01 March 2007

Recombinant glucagon-like peptide-1 (7–36)amide (rGLP-1) was recently shown to cause significant weight loss in type 2 diabetics when administered for 6 weeks as a continuous subcutaneous infusion. The mechanisms responsible for the weight loss are not clarified. In the present study, rGLP-1 was given for 5d by prandial subcutaneous injections (PSI) (76nmol 30min before meals, four times daily; a total of 302·4nmol/24h) or by continuous subcutaneous infusion (CSI) (12·7nmol/h; a total of 304·8nmol/24h). This was performed in nineteen healthy obese subjects (mean age 44·2 (sem 2·5) years; BMI 39·0 (sem 1·2)kg/m2) in a prospective randomised, double-blind, placebo-controlled, cross-over study. Compared with the placebo, rGLP-1 administered as PSI and by CSI generated a 15% reduction in mean food intake per meal (P=0·02) after 5d treatment. A weight loss of 0·55 (sem 0·2) kg (P<0·05) was registered after 5d with PSI of rGLP-1. Gastric emptying rate was reduced during both PSI (P<0·001) and CSI (P<0·05) treatment, but more rapidly and to a greater extent with PSI of rGLP-1. To conclude, a 5d treatment of rGLP-1 at high doses by PSI, but not CSI, promptly slowed gastric emptying as a probable mechanism of action of increased satiety, decreased hunger and, hence, reduced food intake with an ensuing weight loss.

    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
      Available formats
      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about sending content to Dropbox.

      Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
      Available formats
      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about sending content to Google Drive.

      Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects
      Available formats
Corresponding author
*Corresponding author: Dr Erik Näslund, fax +46 8 655 77 66, email
Linked references
Hide All

This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.

A Flint , A Raben , A Astrup & JJ Holst (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515520.

MK Gutniak , C Ørskov , JJ Holst , B Ahrén & S Efendic (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326, 13161322.

MK Gutniak , J Svartberg , PM Hellström , JJ Holst , N Adner & B Ahrén (2001) Antidiabetogenic action of glucagon-like peptide-1 related to administration relative to meal intake in subjects with type 2 diabetes. J Intern Med 250, 8187.

JP Gutzwiller , B Göke , J Drewe , P Hildebrand , S Ketterer , D Handschin , R Winterhalder , D Conen & C Beglinger (1999 b) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 8186.

B Kreymann , MA Ghatei , P Burnett , G Williams , S Kanse , AR Diani & SR Bloom (1989) Characterization of glucagon-like peptide 1 (7–36)amide in the hypothalamus. Brain Res 502, 325331.

PJ Larsen , M Tang-Christensen , JJ Holst & C Ørskov (1997) Distribution of glucagon-like peptide-1 (GLP-1) and other preproglucagon derived peptides in the rat hypothalamus and brain stem. Neuroscience 77, 257270.

R Mentlein , B Gallwitz & WE Schmidt (1993) Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7–36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214, 829835.

S Mojsov , GC Weir & JF Habener (1987) Insulinotropin: glucagon-like peptide I (7–36) co-coded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J Clin Invest 79, 616619.

E Näslund , B Barkeling , N King , MK Gutniak , JE Blundell , JJ Holst & PM Hellström (1999 a) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23, 304311.

E Näslund , P Grybäck , H Jacobsson , PM Hellström (2000) Gastric emptying: a comparison of scintigraphic, marker dilution and paracetamol absorption assessment techniques. Scand J Gastroenterol 35, 375379.

MA Nauck , MM Heimesaat , C Ørskov , JJ Holst , R Ebert & W Creuzfeldt (1993 a) Preserved incretin activity of glucagon-like peptide 1(7–36amide) but not synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91, 301307.

MA Nauck , N Kleine , C Ørskov , JJ Holst , B Willms & W Creuzfeldt (1993 b) Normalization of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7–36amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36, 741744.

MA Nauck , D Wollschläger , J Werner , JJ Holst , C Ørskov , W Creuzfeldt & B Willms (1996) Effects of subcutaneous glucagon-like peptide 1(GLP-1[7–36]amide) in patients with NIDDM. Diabetologia 39, 15461553.

C Ørskov , SS Poulsen , M Møller & JJ Holst (1996) Glucagon-like peptide I receptors in the subfornical organ and area postrema are accessible to circulating glucagon-like peptide I. Diabetes 45, 832835.

C Ørskov , L Rabehøj , A Wettergren , H Kofod & JJ Holst (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43, 535539.

R Ritzel , C Ørskov , JJ Holst & MA Nauck (1995) Pharmacokinetic, insulinotropic, and glucagono-static properties of GLP-1 (7–36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38, 720725.

RE Shapiro & RR Miselis (1985) The central neural connections of the area postrema in the rat. J Comp Neurol 234, 344364.

M Tang-Christensen , N Vrang & PJ Larsen (1998) Glucagon-like peptide 1(7–36)amide's central inhibition of feeding and peripheral inhibition of drinking are abolished by neonatal monosodium glutamate treatment. Diabetes 47, 530537.

JF Todd , JPH Wilding , CMB Edwards , FA Kahn , MA Ghatei & SR Bloom (1997) Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27, 533536.

M-B Toft-Nielsen , S Madsbad & JJ Holst (1999) Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 11341137.

MD Turton , D O'Shea , I Gunn (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 6972.

C Verdich , A Flint , JP Gutzwiller (2001) A meta-analysis of the effect of glucagon-like peptide-1 (7–36)amide on ad libitum food intake in humans. J Clin Endocrinol Metabol 86, 43824389.

M Zander , S Madsbad , JL Madsen & JJ Holst (2002) Effect of 6-week course of glucagon-like peptide-1 on glycemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359, 824830.

Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

British Journal of Nutrition
  • ISSN: 0007-1145
  • EISSN: 1475-2662
  • URL: /core/journals/british-journal-of-nutrition
Please enter your name
Please enter a valid email address
Who would you like to send this to? *